$BMY $EXEL Much awaited CM-9ER RCC trial met both PFS &amp; OS endpoints. Preliminary data suggest Opdivo+Cabo combination could stack up to competition $MRK. The median follow-up time was 18.1 months. 

PFS HR = 0.51 vs. Keytruda+Inlyta's 0.69
OS HR = 0.60 vs. Keytruda+Inlyta's 0.53